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Abbreviations: FP-2, falcipain-2; Suramin, 8,80-[carbonylbis[imino-3,1-phenylene-
carbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulf-
onic acid; AMC, 7-amino-4-methyl coumarin; NF037, 8,80-[carbonylbis[imino-3,1-
phenylenecarbonylimino-3,1-phenylenecarbonylimino]]bis[naphthalene-1,3,5-trisulf-
onic acid] hexasodium salt; NF127, 8,80-[carbonylbis[imino-3,1-phenylenecarbonyli-
mino-3,1-(4-ethylphenylene)-carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid]
hexasodium salt; NF151, 8,80-[carbonylbis[imino-3,1-phenylenecarbonylimino-3,1-
(4-isopropylene)carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium
salt; NF198, 8,80-[carbonylbis[imino-3,1-phenylenecarbonylimino-3,1-(4-isopropyl-
ene)carbonylimino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF157,
8,80-[carbonylbis[imino-3,1-phenylenecarbonylimino-3,1-(4-ﬂuorophenylene)carbon-
ylimino]]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF258, 8,80-[carbon-
ylbis[imino-3,1-phenylenecarbonylimino-3,1-(4-chlorophenylene)carbonylimino]]bis
[naphthalene-1,3,5-trisulfonic acid] hexasodium salt; NF260, 8,80-[carbonylbis[imino-
3,1-phenylenecarbonylimino-3,1-(4-(metoxyphenylene) carbonylimino]]bis[naphtha-
lene-1,3,5-trisulfonic acid] hexasodium salt; NF222, 8,80-[carbonylbis[imino-3,1-
phenylenecarbonylimino-3,1-(4-(metoxymethyl)phenylene)carbonylimino]]bis[naph-
thalene-1,3,5-trisulfonic acid] hexasodium salt; NF023, 8,80-[carbonylbis[imino-3,1-
phenylenecarbonylimino]bis[naphthalene-1,3,5-trisulfonic acid] hexasodium salt;
NF058, 8,80-[carbonylbis[imino-3,1-(4-methylphenylene)carbonylimino]]bis[naphtha-
lene-1,3,5-trisulfonic acid] hexasodium salt; MK-HU1, 4,40-[carbonylbis[imino-3,1-
phenylenecarbonylimino]]bis[benzene-1,3-disulfonic acid] tetrasodium salt.
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AllosteryFalcipain-2 is a cysteine protease of the malaria parasite Plasmodium falciparum that plays a key role in
the hydrolysis of hemoglobin, a process that is required by intraerythrocytic parasites to obtain amino
acids. In this work we show that the polysulfonated napthylurea suramin is capable of binding to falci-
pain-2, inhibiting its catalytic activity at nanomolar concentrations against both synthetic substrates and
the natural substrate hemoglobin. Kinetic measurements suggest that the inhibition occurs through an
noncompetitive allosteric mechanism, eliciting substrate inhibition. Smaller suramin analogues and
those with substituted methyl groups also showed inhibition within the nanomolar range. Our results
identify the suramin family as a potential starting point for the design of falcipain-2 inhibitor antimala-
rials that act through a novel inhibition mechanism.
 2013 Elsevier Ltd. All rights reserved.1. IntroductionMalaria, caused by the Plasmodium parasite, is one of the most
serious public health problems worldwide. Hundreds of millions
of cases of malaria occur each year, resulting in about a million
deaths, mostly from Plasmodium falciparum.1 Although malaria is a
treatable and curable disease, P. falciparum is a highly adaptable
parasite,2 resulting in growing resistance to antimalarial medicines.
Currently, the most effective treatment for falciparum malaria is
artemisinin-based combination therapy (ACT), but this strategy is
now threatened by emergence of parasites with decreased sensitiv-
ity to artemisinins in Southeast Asia.3,4 New antimalarial agents,
ideally acting against novel targets, are thus greatly needed.5–10
During the complex life cycle of the malaria parasite, only the
erythrocytic cycle is responsible for human disease symptoms,
and thus the design of drugs to treat active infections focuses on
erythrocytic parasites. Intraerythrocytic parasites utilize multiple
proteases to hydrolyze hemoglobin in an acidic food vacuole to
provide amino acids for parasite protein synthesis.11,12 The key
cysteine proteases involved in hemoglobin digestion are falci-
pain-2 and falcipain-313–16 and these enzymes are validated drug
targets against which new classes of inhibitors are being
pursued.12,17–19 Treatment with cysteine protease inhibitors blocks
hemoglobin hydrolysis, with the accumulation of undigested
Figure 1. Schematic chemical structures of suramin analogues. Substituent (–R)
groups are as listed in Table 1. (1) is suramin for R = H, (2) NF023 and (3) is MK-
HU1.
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development.20–22 The discovery of several speciﬁc inhibitors for
the falcipain family had been reported in the last years.19,23 The
high resolution crystal structure of falcipain-2 and falcipain-3 has
been solved24,25 and recent effort has gone into the characteriza-
tion of novel active site inhibitors.26–30 However, allosteric modu-
lation of the activity of falcipains has not been described.
Upon hemoglobin digestion by falcipains, peptide fragments are
released alongwith heme.31–34 In solution, heme leads to the gener-
ation of toxic oxygen species, which is minimized in the digestive
vacuole through detoxiﬁcation of heme into hemozoin.33,35,36 Inhi-Figure 2. Effect of suramin on falcipain-2 activity. (A) Hemoglobinase activity of falcipa
Methods, reaction products were resolved by SDS–PAGE, and remaining hemoglobin was
falcipain-2 (t = 0); (3) human hemoglobin + 20 nM falcipain-2 (t = 90 min); (4) human he
of falcipain-2 against the ﬂuorogenic subtrate Z-Phe-Arg-AMC. The peptide was incubat
varying concentration of suramin, and hydrolysis was assessed ﬂuorometrically. Results
represent non-linear regression of data according to Eq. 2.bition of both falcipain-2 function and heme crystallization have
long been considered as therapeutic approaches for the treatment
of malaria.16,37–42 Indeed, aminoquinolines such as chloroquine
act to disrupt the biocrystallization of heme.43,44
Suramin is a polysulfonated polyaromatic symmetrical urea
(Fig. 1) that is used in the treatment of trypanosomiasis and oncho-
cerciasis.45 Suramin has also been shown in P. falciparum to inhibit
invasion of HepG2 cells by sporozoites,46 merozoite surface pro-
tein-1 secondary processing, and erythrocyte invasion by merozo-
ites.47 In a search for novel ligand prototypes and motifs targeting
falcipains, we investigated interactionswith suramin, amodel poly-
sulfonated compound. Our data show that suramin binds to falci-
pain-2, modulating its hydrolytic activity through a novel
mechanism for this enzyme. Further, we report here an extended
evaluation of suramin analogues anddiscuss implications of alloste-
ric inhibition of falcipains.2. Results
2.1. Suramin inhibits falcipain-2
To evaluate the effect of suramin on falcipain-2, we ﬁrst
conducted a hemoglobinase assay with the natural falcipain-2 sub-
strate, human hemoglobin. Hemoglobin was hydrolyzed by falci-
pain-2, as expected, and this hydrolysis was prevented in the
presence of 200 nM suramin (Fig. 2A).
We also tested the effect of suramin on the hydrolytic activity of
falcipain-2 against the ﬂuorogenic substrate Z-Phe-Arg-AMC.
Hydrolysis of the substrate was inhibited, with an IC50 of
95 ± 1.5 nM (Fig. 2B).2.2. Stoichiometry of binding
In order to characterize the stoichiometry of the suramin/falci-
pain-2 complex, we performed an isothermal titration of suramin
to a ﬁxed amount of falcipain-2 (5 lM), well above the IC50 of
95 nM. The tryptophan ﬂuorescence of falcipain-2 was measured
following the progressive addition of suramin, revealing a steep de-
crease in ﬂuorescence due to suppression by suramin (Fig. 3A).
Above amolar suramin:falcipain-2 ratio of close to 1:1we observed
loss of dependence of ﬂuorescence suppression on the suraminin-2. Hemoglobin was incubated with falcipain-2 under the conditions described in
quantiﬁed by densitometry. (1) human hemoglobin; (2) human hemoglobin + 20 nM
moglobin + 20 nM falcipain-2 + 200 nM suramin (t = 90 min). (B) Hydrolytic activity
ed with falcipain-2 under the conditions described in experimental procedure with
represent the average of three independent experiments ± SEM and the solid lines
Figure 3. Stoichiometric binding assay for suramin and falcipain-2. The stoichiometry was accessed by monitoring changes in tryptophan ﬂuorescence of falcipain-2 (ex
295 nm, em 340 nm) as a function of increasing suramin concentration. (A) falcipain-2 titration isotherm with suramin monitored by changes in tryptophan ﬂuorescence; (B)
ﬁrst derivative of data in (A), showing the inﬂection point at a 1:1 molar ratio.
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curve of the titration data (Fig. 3B). These data suggest a binding
stoichiometry of one suramin molecule per falcipain-2 molecule.
2.3. Mechanism for suramin inhibition of falcipain-2
In order to shed light on the mechanism of the suramin/falci-
pain-2 interaction, we evaluated the dependence of Z-Phe-Arg-
AMC hydrolysis on falcipain-2 turnover in the presence of varying
amounts of suramin. In the absence of suramin, the reaction fol-
lowed classical Michaelis–Menten kinetics up to 100 lM substrate,
with a hyperbolic behavior. In the presence of increasing amounts
of suramin the dependence of the hydrolytic activity of falcipain-2Figure 4. Effect of suramin on falcipain-2 catalytic activity. (A) Z-Phe-Arg-AMC hydrol
Lineweaver–Burk plots of data from (A). (C) Dependence of falcipain-2 inhibition by sur
regression with Eq. 2. (D) Wyman’s linkage plot of the logarithm of the suramin IC50 over
IC50 corresponds to values calculated as depicted in (C). The solid line corresponds to the
experiments ± SD.on substrate concentration showed a biphasic behavior, increasing
according to the substrate concentration at lower concentrations,
followed by a decrease at higher substrate concentrations
(Fig. 4A). Lineweaver–Burk plots for substrate hydrolysis in the
presence of varying concentration of suramin showed a drift from
the linear dependence of 1/V over 1/S when activity was measured
in the presence of increasing amounts of suramin (Fig. 4B). The bi-
phasic proﬁle, with a rise in enzyme activity followed by a decrease
at higher substrate concentrations is typical for a mechanism
involving enzyme inhibition by the substrate.48–51 Further data
analysis allowed the estimation of the suramin IC50 for reactions
conducted at varying substrate concentration (Fig. 4C) using a link-
age plot,52,53 according toysis by falcipain-2 (20 nM) in the presence varying concentration of suramin. (B)
amin on substrate concentration (data from (A). Lines correspond to the non-linear
falcipain-2 activity as a function of the logarithm of the substrate concentration. The
best ﬁtting of Eq. 1 to the data. Symbols represent the average of three independent
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The slope of log IC50 versus log [substrate], the log of substrate
concentration, gives DNsubstrate, the number of substrate molecules
associated with falcipain-2 upon treatment with suramin. Fig-
ure 4D shows the decrease in IC50 with increasing substrate con-
centration, suggesting different substrate association states for
each falcipain-2/suramin association condition. By adjusting Eq. 1
to the experimental data in Figure 4D we calculated the change
in substrate association state DNsubstrate that follows falcipain-2
inhibition by suramin at 2 units. Thus, in the range of suramin
and substrate concentrations evaluated (where substrate inhibi-
tion occurs), the cooperativity of suramin and substrate binding
appears to be linked, meaning that a conformational equilibrium
holds in falcipain-2 upon suramin binding, eliciting a novel regula-
tory substrate binding site in the enzyme. These data appear to un-Figure 5. Inhibitory activity of suramin analogues against falcipain-2. Assays were pe
presence of varying concentration of suramin and suramin analogues. (A) Analogues wi
halogen substituent; (D) short urea analogues. Symbols represent the average of three in
ﬁt with Eq. 2.
Table 1
Inhibitory activity of suramin analogues. IC50 ± standard error were calculated by
adjusting Eq. 2 to the data in Figure 4
Compound –R IC50 (nM)
1a (NF037) –H 36 ± 7
1b (Suramin) –CH3 95 ± 1.5
1c (NF127) –CH2CH3 80 ± 21
1d (NF151) –CH(CH3)2 111 ± 5
1e (NF198) –C6H5 62 ± 11
1f (NF260) –OCH3 67 ± 5
1g (NF222) –CH2OCH3 60 ± 11
1h (NF258) –Cl 78 ± 11
1i (NF157) –F 42 ± 7
2 (NF023) –H 167 ± 5
3 (MK-HU1) –H 98 ± 32veil a novel inhibition mechanism for falcipain-2, through the
binding and stabilization of the enzyme/substrate/inhibitor com-
plex, a characteristic feature of uncompetitive inhibition, but
which allows the subsequent allosteric binding of a second sub-
strate molecule to falcipain-2, resulting in its inhibition.
2.4. Characterization of the activity of suramin analogues
against falcipain-2
To further characterize the molecular mechanism of falcipain-2
inhibition by suramin, we evaluated compounds with the replace-
ment of the methyl groups of suramin by a series of non-polar (e.g.,
alkyl, phenyl, halogen and methoxy substituents) or polar (with
halogen heteroatoms) substituents (Table 1, Fig. 5).
Regardless of the nature of the modiﬁcation, all compounds
tested showed similar inhibition potency to that of suramin, all
with IC50s in the nanomolar range (Fig. 5, Table 1). The most effec-
tive inhibitor was 1a, which bears a hydrogen substituent instead
of the methyl group of suramin. These data suggest that the pres-
ence of substituents with larger volume at this position might ex-
ert a negative inﬂuence on the inhibition proﬁle.
We also examined the effect of decreasing the polysulfonated
character of the polyaromatic symmetrical urea of suramin, as well
as reducing its size. Compounds 2 and 3 displayed somewhat high-
er IC50 compared to its analogue 1a. These data indicate that the
oversulfonated character of suramin (1b) and some analogues is
not a determining factor for falcipain-2 binding and inhibition.
Therefore, a minimal chemical entity comprising the sulfonated
phenyl-amide might be sufﬁcient for the inhibitory activity of sur-
amin analogues.rformed in the presence of 50 lM Z-Phe-Arg-AMC and 20 nM falcipain-2, in the
th apolar substituents; (B) analogues with polar substituents; (C) analogues with a
dependent experiments ± SD and the solid line represents the best non-linear curve
Figure 6. Structural representation of falcipain-2-suramin interaction. (A) Struc-
tural alignment of the ﬁve available falcipain-2 crystal structures. Structural models
were superposed with PyMOL68 and are displayed in ribbons, showing the
similarity between the structures despite the dissimilar ligands used in crystalli-
zation, as follows: E64 (PDB entry 3BPF), iodoacetamide (PDB entry 2GHU),
chagasin (PDB entry 2OUL), PbiCP (PDB entry 3PNR) and cystatin (PDB entry 1YVB).
(B) falcipain-2 in complex with E64 (carbons in green) and docked with suramin
(from PDB entry 2H9T, carbons in grey) using HEX.67 (C) the structure shown in (B),
rotated 90 in the x-axis.
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The structures of falcipain-2 solved so far are similar, with super-
position Ca RMSDof less than 1 Å. Comparative analysis does not al-
low the identiﬁcation of large differences between them (Fig. 6A),
and no detectable novel binding motif belongs to any particular
structure. Macromolecular docking of suramin (PDB entry 2H9T)
to falcipain-2 (PDB entry 3BPF, for a falcipain-2-E64 complex) re-
sulted in a best scorewith the suraminmolecule docked in the vicin-ity of the falcipain-2 active site (Fig. 6B and C), in a cleft located
between the active site and the falcipain-2 ‘arm’. E64 is an inhibitor
of cysteine proteases, binding irreversibly to the active site. Suramin
interaction with falcipain-2 in the docked complex spans from
His197 and Lys184 to Asn173 and Gln171, and these two amino
acids are located adjacent to the guanidine moiety of the E64 ligand
in the falcipain-2 crystal structure used in this docking. These data
allowus toobtainanoverall estimationof the extentof surface inter-
action between falcipain-2 and suramin, which is also indicative of
the existence of a region in the falcipain-2 structure for interaction
with synthetic substrates, hemoglobin or hemoglobin fragments.
3. Discussion
We have found that suramin binds to and inhibits falcipain-2 at
nanomolar concentrations. It has been shown that suramin might
exert control over several biological functions, as it is a ﬁrst-line
drug to treat African trypanosomiasis54 and it acts on a variety of
processes in cancer, hemostasis, among others.47,55–61 Despite hav-
ing some good characteristics for pharmaceutical use, such as met-
abolic stability and long half life in plasma, suramin also interacts
nonspeciﬁcally with several targets, leading to signiﬁcant toxicity.
Therefore suramin, and likely suramin analogues are not appropri-
ate for treatment of malaria. However, suramin proved useful for
the identiﬁcation of novel molecular features in falcipain-2.
This report describes the ability of suramin and some of its ana-
logues to interact with recombinant falcipain-2. We have shown
that suramin inhibits activity of falcipain-2 against both a peptide
substrate and its natural substrate, hemoglobin. Suramin ana-
logues with modulation of the main substituent at the methyl
group of suramin and with varying degrees of sulfonation and
length had activities similar to that of suramin. Kinetic measure-
ments revealed that falcipain-2 is subject to substrate inhibition
once an allosteric effector—in this case suramin—binds to the en-
zyme. Suramin forms a uni-molecular complex with falcipain-2,
which is inhibited at high concentration of substrate. The substrate
inhibition effect has not been previously reported for falcipain-2,
and it was only observed here when the activity was conducted
in the presence of the non-competitive inhibitor suramin. It is
likely that the binding of suramin to falcipain-2 unveils a second
substrate binding site, resulting in the allosteric inhibition of falci-
pain-2. We do not exclude that this phenomenonmay occurs in the
absence of suramin or any other heterotropic ligand, although sur-
amin assists in unveiling this effect.
The hydrolysis of hemoglobin and hemoglobin fragments by fal-
cipain-2 occurs at the active site. Substrate inhibition precludes the
existence of a second substrate binding site, distinct from the ac-
tive site. The falcipain-2 ‘arm’, which is located well apart from
the active site, has been characterized as a hemoglobin binding
exosite.25,62 In light of our present results, we suggest that the fal-
cipain-2 arm may function as the negative heterotropic effector
over falcipain-2 catalytic activity.
Falcipains, along with other proteases in the P. falciparum food
vacuole, are responsible for the digestion of hemoglobin, and inhi-
bition of falcipain-2 and related cysteine proteases blocks parasite
development.12 Cleavage of falcipain’s natural substrate, hemoglo-
bin, generates free heme, which is known to be toxic and a cause of
oxidative stress. A negative-feedback pathway, in which the bind-
ing of a second hemoglobin molecule or fragments to the enzyme
could reduce falcipain turnover, may facilitate the conversion of
heme into hemozoin. We envision that inside the food vacuole fal-
cipain-2 may not be fully active. Instead, falcipain-2 may be par-
tially inhibited by hemoglobin and its peptide fragments and by
non-crystallized heme. We speculate that free heme moieties
might behave as allosteric effectors, inhibiting of falcipains, and
resulting in a mechanism for protection from toxic species of heme
3672 A. F. Marques et al. / Bioorg. Med. Chem. 21 (2013) 3667–3673in solution. Upon conversion of heme into hemozoin, inhibition
would cease, and falcipain-2 would reach higher activity levels,
releasing peptides and additional heme, in a tightly balanced
mechanism, potentially minimizing the risks for oxidative damage
that would result in death of the parasite. However, this hypothesis
remains to be further investigated. The design of novel allosteric,
non-competitive inhibitors targeting falcipain-2 at the suramin
binding site will be helpful for further characterization of this reg-
ulatory site and potentially to facilitate the discovery of novel anti-
malarial therapeutics.4. Experimental procedures
4.1. Material
Suramin was from Sigma Chemicals (St. Louis, MO). Suramin
analogues were synthesized as described elsewhere.57 All other re-
agents were of analytical grade. All buffers and solutions were pre-
pared just prior to use.
4.2. Construction, expression and puriﬁcation of recombinant
falcipain-2
The241-amino-acidmaturedomainof falcipain-2wasexpressed
in Escherichia coli, puriﬁed by high-afﬁnity Ni column chromatogra-
phy, and refolded to its active form as described elsewhere.13,63
4.3. Assays of falcipain-2 hemoglobinase activity
Assays of hemoglobinase activity were carried out in the pres-
ence of 0.1 mg/ml of human hemoglobin (Sigma–Aldrich, Brazil)
in 100 mM sodium acetate buffer, 10 mM DTT, 10% glycerol, pH
5.5, 20 nM falcipain-2, in the presence or absence of suramin
(200 nM) at 37 C for 90 min. The reactions were quenched by
addition of denaturing SDS sample buffer and products were re-
solved by 15% SDS–PAGE and stained with Coomassie Blue R-
250, followed by densitometry with ImageJ.64
4.4. Assays of falcipain-2 peptidolytic activity
Assays of falcipain-2 (20 nM) activity were carried out as previ-
ously described65 in 100 mM sodium acetate buffer, 10 mM DTT,
10% glycerol, pH 5.5,66 in a ﬁnal volume of 200 ll containing the
ﬂuorogenic substrate Z-Phe-Arg-AMC (50 lM). The hydrolysis
was continuously monitored as the ﬂuorescence of released AMC
(excitation 355 nm, emission 460 nm) over 30 min at room tem-
perature (23 ± 2 C) with a SpectraMax M5 (Molecular Devices)
spectroﬂuorimeter. At least three independent experiments were
used for each curve.
4.5. Measurement of the half maximal inhibitory concentration
(IC50) for suramin and suramin analogues
The activities were measured in 96-well microtitre opaque
plates at room temperature, as described above, in the presence
of varying concentrations of suramin analogues. The IC50 values
were calculated from the percent enzyme activity as a function
of inhibitor concentration, and data points were ﬁtted to a logistic
four-parameter curve with Sigma Plot software (Jandel Scientiﬁc)
according to the equation:
y ¼ minþ maxmin
1þ ð xIC50 Þ
Hillslope ð2Þ
where y is the enzyme normalized activity, min is the minimum
activity value and max is the maximum activity value observed.At least three independent experiments were used to determine
the half maximal inhibitory concentration (IC50) values for each
compound.
4.6. Tryptophan ﬂuorescence measurements of falcipain-2
Suramin binding to falcipain-2 was assessed by measurement of
the ﬂuorescence of falcipain-2 tryptophan residues in a Jasco FP-
6300 spectroﬂuorimeter (Jasco Inc, USA). Assays included 5 lM fal-
cipain-2 in 100 mM sodium acetate buffer pH 5.5%, 5% glycerol,
10 mM DTT, and varying concentrations of suramin from a stock
solution in the same buffer, with excitation at 295 nm and emis-
sion at 340 nm. The maximum dilution was 10%, and ﬂuorescence
and protein concentrations were corrected accordingly.
4.7. Molecular docking between suramin and falcipain-2
Molecular docking was performed using the program Hex67
through its webserver (http://hexserver.loria.fr/) and structures
for falcipain-2 (PDB entry 3BPF, for falcipain-2/E64 complex)25
and suramin (PDB entry 2H9T),59 with 360 rotational dock in
7.5 steps, using either surface or surface + electrostatic comple-
mentarities functions.
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